Key result
Catheter-based percutaneous renal denervation therapy is safe and effective in the treatment of resistant hypertension.
Why the study?
Does catheter-based percutaneous renal denervation therapy improve outcomes in patients with drug-resistant hypertension?
Does catheter-based percutaneous renal denervation therapy improve outcomes in patients with drug-resistant hypertension?
This review highlights that catheter-based percutaneous renal denervation is a safe and effective emerging therapy for drug-resistant hypertension.
May support use in resistant hypertension; leaves open need for confirmatory randomized trials.
Resistant hypertension remains a challenging issue even for modern medicine. Therefore, research is focusing on the development of new technologies to optimize the treatment of this condition. It has been demonstrated that the dysfunction of the sympathetic nervous system is crucial in the development and maintenance of advanced stages of hypertension. Based on these findings, clinical trials have recently shown that catheter-based percutaneous renal denervation therapy is safe and effective in the treatment of resistant hypertension. This review discusses the current scientific knowledge of renal denervation therapy in resistant hypertension, including the different methods that have been described in the literature so far, as well as limitations of the available data. Furthermore, new potential targets for this fascinating therapy will be addressed.
No takes yet. Share an insight, caveat, or question.
Prochnau et al. (2013) conducted a review in resistant hypertension. catheter-based percutaneous renal denervation therapy was evaluated. Catheter-based percutaneous renal denervation therapy is safe and effective in the treatment of resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: